Your browser doesn't support javascript.
loading
Fistula Risk Score for Auditing Pancreatoduodenectomy: The Auditing-FRS.
van Dongen, Jelle C; van Dam, Jacob L; Besselink, Marc G; Bonsing, Bert A; Bosscha, Koop; Busch, Olivier R; van Dam, Ronald M; Festen, Sebastiaan; van der Harst, Erwin; de Hingh, Ignace H; Kazemier, Geert; Liem, Mike S L; de Meijer, Vincent E; Mieog, Jan S D; Molenaar, Izaak Q; Patijn, Gijs A; van Santvoort, Hjalmar C; Wijsman, Jan H; Stommel, Martijn W J; Wit, Fennie; De Wilde, Roeland F; van Eijck, Casper H J; Groot Koerkamp, Bas.
Afiliación
  • van Dongen JC; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • van Dam JL; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Besselink MG; Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Bonsing BA; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Bosscha K; Department of Surgery, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
  • Busch OR; Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • van Dam RM; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Festen S; Department of Surgery, OLVG, Amsterdam, The Netherlands.
  • van der Harst E; Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
  • de Hingh IH; Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
  • Kazemier G; Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Liem MSL; Department of Surgery, Medisch Spectrum Twente, Enschede, The Netherlands.
  • de Meijer VE; Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands.
  • Mieog JSD; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Molenaar IQ; Department of Surgery, Regional Academic Cancer Center Utrecht, St Antonius Hospital Nieuwegein and University Medical Center Utrecht, Utrecht, The Netherlands.
  • Patijn GA; Department of Surgery, Isala, Zwolle, The Netherlands.
  • van Santvoort HC; Department of Surgery, Regional Academic Cancer Center Utrecht, St Antonius Hospital Nieuwegein and University Medical Center Utrecht, Utrecht, The Netherlands.
  • Wijsman JH; Department of Surgery, Amphia Hospital, Breda, The Netherlands.
  • Stommel MWJ; Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Wit F; Department of Surgery, Tjongerschans, Heerenveen, The Netherlands.
  • De Wilde RF; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • van Eijck CHJ; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Groot Koerkamp B; Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Ann Surg ; 278(2): e272-e277, 2023 08 01.
Article en En | MEDLINE | ID: mdl-35837978
ABSTRACT

OBJECTIVE:

To develop a fistula risk score for auditing, to be able to compare postoperative pancreatic fistula (POPF) after pancreatoduodenectomy among hospitals.

BACKGROUND:

For proper comparisons of outcomes in surgical audits, case-mix variation should be accounted for.

METHODS:

This study included consecutive patients after pancreatoduodenectomy from the mandatory nationwide Dutch Pancreatic Cancer Audit. Derivation of the score was performed with the data from 2014 to 2018 and validation with 2019 to 2020 data. The primary endpoint of the study was POPF (grade B or C). Multivariable logistic regression analysis was performed for case-mix adjustment of known risk factors.

RESULTS:

In the derivation cohort, 3271 patients were included, of whom 479 (14.6%) developed POPF. Male sex [odds ratio (OR)=1.34; 95% confidence interval (CI) 1.09-1.66], higher body mass index (OR=1.07; 95% CI 1.05-1.10), a final diagnosis other than pancreatic ductal adenocarcinoma/pancreatitis (OR=2.41; 95% CI 1.90-3.06), and a smaller duct diameter (OR=1.43/mm decrease; 95% CI 1.32-1.55) were independently associated with POPF. Diabetes mellitus (OR=0.73; 95% CI 0.55-0.98) was independently associated with a decreased risk of POPF. Model discrimination was good with a C -statistic of 0.73 in the derivation cohort and 0.75 in the validation cohort (n=913). Hospitals differed in particular in the proportion of pancreatic ductal adenocarcinoma/pancreatitis patients, ranging from 36.0% to 58.1%. The observed POPF risk per center ranged from 2.9% to 25.4%. The expected POPF rate based on the 5 risk factors ranged from 11.6% to 18.0% among hospitals.

CONCLUSIONS:

The auditing fistula risk score was successful in case-mix adjustment and enables fair comparisons of POPF rates among hospitals.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pancreatitis / Carcinoma Ductal Pancreático Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Pancreatitis / Carcinoma Ductal Pancreático Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article